ArticleBreast cancer (Tokyo, Japan)2018

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.

Hitomi Sakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.